The survey aimed to assess the implementation of WHO tuberculosis (TB) preventive treatment guidelines in high-burden countries (HBCs) and identify barriers to scaling up these therapies.
Results showed incomplete implementation of guidelines in many HBCs, with countries like Angola and India prioritizing active TB treatment over latent TB infection (LTBI) management.
Key obstacles included product shortages (like PPD), high costs (particularly for IGRA testing), and limited availability of new treatments such as rifapentine.